Main Industry
Biotechnology
Main Product/Service
New drug development, custom chemical synthesis, pharmacological activity testing, analytical testing, and development of novel therapeutics targeting irritable bowel syndrome (IBS)-related chronic abdominal pain.
Founded Year
2025
Unified Business No.
60713647
Status
Active
Total Paid-in
Capital
10,550,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LYNTONIX is a biotech startup spun out from a National Taiwan University research team. It focuses on developing non-addictive treatments for chronic pain, particularly irritable bowel syndrome (IBS)-related abdominal pain. Its lead candidate LTX-568 targets a newly discovered pain mechanism and has completed preclinical studies, with plans for IND-enabling studies and clinical trials in the coming years.
